Gilead Sciences (GILD) PT Raised to $134 at Piper Jaffray on Another 'Beat and Raise'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq futures tick up as tech steadies, Micron earnings eyed
- Brent extends losses on expectations of smoother crude flows via Hormuz
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Gilead Sciences Announces Second Quarter 2015 Financial Results
July 28, 2015 4:01 PM EDT- Over 180,000 U.S. and EU Patients Treated Year-to-Date with Sovaldi or Harvoni -
- Product Sales of $8.1 billion -
- Non-GAAP EPS of $3.15 per share -
- Revised 2015 Full Year Guidance -
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the second quarter ended June 30, 2015. The financial results that follow represent a year over year comparison of second quarter 2015 to the second quarter 2014. Total revenues... More
